Some AASLD abstract titles for $VRUS $ACHN $BMY $VRTX $JNJ/Medivir
$VRUS
"#225 Once-Daily PSI-7977 Plus Peg/RBV in Treatment-naïve Patients with HCV GT1: Robust End of Treatment Response Rates are Sustained Post-treatment."
"#34 Once Daily PSI-7977 plus RBV: Pegylated interferon-ALFA not required for Complete Rapid viral response in Treatment-naïve Patients with HCV GT2 or GT3."
"#391 PSI-7977 Has No Effect on QTcF Intervals at Therapeutic or Supratherapeutic Doses."
$ACHN
"#1341. High Rapid Virologic Response(RVR) with ACH-1625 Daily Dosing plus PegIFN-alpha 2a/RBV in a 28-day Phase 2a Trial"
$BMY
"#227. BMS-790052, A NS5A Replication Complex Inhibitor, Combined with Peginterferon Alfa-2a and Ribivirin in Treatment-Naive HCV-Genotype 1 or 4 Patients: Phase 2b AI444010 Study Interim Week 12 Results."
"#LB-22. BMS-790052, an NS5A Replication Complex Inhibitor, in Combination with Peginterferon Alpha-2b and Ribavirin in Japanese Treatment-Naïve and Nonresponder Patients with Chronic HCV Genotype 1 Infection."
"#LB-20. Combination Therapy of Treatment-Naïve and Nonresponder Patients with HCV Genotype 1 Infection with BMS-790052, an NS5A Replication Complex Inhibitor, in Combination with Peginterferon Alfa-2a and Ribavirin. "
"#LB-4. Dual Oral Combination Therapy with the NS5A Inhibitor BMS-790052 and the NS3 Protease Inhibitor BMS-650032 Achieved 90% Sustained Virologic Response (SVR12) in HCV Genotype 1b-Infected Null Responders."
$VRTX
"#LB-14. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 Weeks: ZENITH study, SVR12 interim analysis."
$JNJ/Medivir
"#LB-5. TMC435 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 1 PATIENTS: FINAL ANALYSIS OF THE PILLAR PHASE IIB STUDY."
"#1329. TMC435 in combination with peginterferon alpha-2a/ribavirin in treatment-naïve patients infected with HCV genotype 1: virology analysis of the PILLAR study"
News 
Market Data 
Discover 
